Published online before print December 12, 2008, doi: 10.1161/CIRCRESAHA.108.182014
© 2009 American Heart Association, Inc.
Integrative Physiology |
Interleukin-6 Overexpression Induces Pulmonary Hypertension
From the Pulmonary Critical Care Unit (M.K.S., O.L.S., N.K., C.A.H., A.B.W.), Department of Medicine; and Department of Pathology (E.J.M.), Massachusetts General Hospital, Harvard Medical School, Boston.
Correspondence to M. Kathryn Steiner, Division of Pulmonary Critical Care Medicine, University of Massachusetts Memorial Medical Center, 55 Lake Ave North, Worcester, MA 01655. E-mail marciakathryn.steiner{at}umassmemorial.org
Inflammatory cytokine interleukin (IL)-6 is elevated in the serum and lungs of patients with pulmonary artery hypertension (PAH). Several animal models of PAH cite the potential role of inflammatory mediators. We investigated role of IL-6 in the pathogenesis of pulmonary vascular disease. Indices of pulmonary vascular remodeling were measured in lung-specific IL-6–overexpressing transgenic mice (Tg+) and compared to wild-type (Tg–) controls in both normoxic and chronic hypoxic conditions. The Tg+ mice exhibited elevated right ventricular systolic pressures and right ventricular hypertrophy with corresponding pulmonary vasculopathic changes, all of which were exacerbated by chronic hypoxia. IL-6 overexpression increased muscularization of the proximal arterial tree, and hypoxia enhanced this effect. It also reproduced the muscularization and proliferative arteriopathy seen in the distal arteriolar vessels of PAH patients. The latter was characterized by the formation of occlusive neointimal angioproliferative lesions that worsened with hypoxia and were composed of endothelial cells and T-lymphocytes. IL-6–induced arteriopathic changes were accompanied by activation of proangiogenic factor, vascular endothelial growth factor, the proproliferative kinase extracellular signal-regulated kinase, proproliferative transcription factors c-MYC and MAX, and the antiapoptotic proteins survivin and Bcl-2 and downregulation of the growth inhibitor transforming growth factor-β and proapoptotic kinases JNK and p38. These findings suggest that IL-6 promotes the development and progression of pulmonary vascular remodeling and PAH through proproliferative antiapoptotic mechanisms.
Key Words: interleukin-6 • pulmonary artery hypertension • proliferation
This article has been cited by other articles:
 |
|
 |
|
  K. R. Stenmark, B. Meyrick, N. Galie, W. J. Mooi, and I. F. McMurtry Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure Am J Physiol Lung Cell Mol Physiol, December 1, 2009; 297(6): L1013 - L1032. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Johns and K. Yamaji-Kegan Unveiling cell phenotypes in lung vascular remodeling Am J Physiol Lung Cell Mol Physiol, December 1, 2009; 297(6): L1056 - L1058. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Strassheim, S. R. Riddle, D. L. Burke, M. W. Geraci, and K. R. Stenmark Prostacyclin Inhibits IFN-{gamma}-Stimulated Cytokine Expression by Reduced Recruitment of CBP/p300 to STAT1 in a SOCS-1-Independent Manner J. Immunol., December 1, 2009; 183(11): 6981 - 6988. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Kugathasan, J. B. Ray, Y. Deng, E. Rezaei, D. J. Dumont, and D. J. Stewart The angiopietin-1-Tie2 pathway prevents rather than promotes pulmonary arterial hypertension in transgenic mice J. Exp. Med., September 28, 2009; 206(10): 2221 - 2234. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. Steiner World Health Organization Class III COPD-Associated Pulmonary Hypertension: Are We There Yet in Understanding the Pathobiology of the Disease? Chest, September 1, 2009; 136(3): 658 - 659. [Full Text] [PDF]
|
|
|
|
|
|
A. Chaouat, L. Savale, C. Chouaid, L. Tu, B. Sztrymf, M. Canuet, B. Maitre, B. Housset, C. Brandt, P. Le Corvoisier, et al. Role for Interleukin-6 in COPD-Related Pulmonary Hypertension Chest, September 1, 2009; 136(3): 678 - 687. [Abstract] [Full Text] [PDF]
|
|